Janku Filip 4

What Happened Filip Janku, Chief Medical Officer of Monte Rosa Therapeutics (GLUE), exercised stock options and immediately sold the resulting shares on June 30, 2026. He exercised 5,407 shares at an exercise price of $13.41 (cost $72,508) and sold those 5,407 shares in an open-market transaction at $24.50 each, generating proceeds of $132,472. The filing also reports a related derivative disposition at $0 tied to the option conversion.

Key Details

• Transaction date: June 30, 2026 (filed July 1, 2026) — appears timely.
• Option exercise (code M): 5,407 shares at $13.41; total exercise cost $72,508.
• Sale (code S): 5,407 shares at $24.50; total proceeds $132,472.
• Additional note (F2): Includes 620 shares acquired under the issuer’s 2021 Employee Stock Purchase Program on June 30, 2026.
• Option status (F3): Shares underlying the option were fully vested and exercisable.
• Plan (F1): Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.
• Shares owned after transaction: not specified in the provided filing excerpt.

Context This was an exercise-and-sell (cash-out) of vested options executed under a pre-established 10b5-1 plan — a common way for insiders to convert options to cash while following a written trading schedule. The main economic events are the $72.5k paid to exercise and the $132.5k in sale proceeds; the filing’s footnotes confirm vesting and the ESPP acquisition. These transactions are routine insider liquidity actions and, by themselves, do not indicate the company’s future performance.